Surgery Partners recently announced its financial performance for the fourth quarter, revealing adjusted earnings of merely 12 cents per share, substantially below the anticipated 30 cents. While total sales saw a modest increase of 2.4% year-over-year, reaching $885 million and surpassing the $866.47 million consensus, the company's adjusted EBITDA for the quarter stood at $156.9 million, a decline from $163.8 million reported in the same period last year. Furthermore, cash flows from operating activities also decreased from $111.4 million in Q4 2024 to $103.4 million in Q4 2025. This downturn, coupled with a conservative outlook for 2026, which projects sales between $3.35 billion and $3.45 billion against an analyst consensus of $3.56 billion, has led to a significant drop in the company's stock value.
Surgery Partners Navigates 'Headwinds' as Stock Hits 52-Week Low Amidst Disappointing Financials
On March 3, 2026, Surgery Partners (NASDAQ: SGRY) found its shares tumbling in Tuesday's premarket trading, reacting to the recent financial disclosures. The company's fourth-quarter results for 2025 painted a challenging picture, missing analyst expectations for earnings and providing a cautious forecast for the fiscal year 2026. Adjusted earnings were reported at 12 cents per share, a stark contrast to the 30 cents anticipated by experts. Although sales climbed to $885 million, slightly exceeding the $866.47 million consensus, the underlying financial health showed signs of strain with a dip in adjusted EBITDA to $156.9 million from $163.8 million in the prior year's fourth quarter. Operational cash flows also experienced a decline, reinforcing concerns among investors.
Despite these setbacks, Eric Evans, the CEO, acknowledged "significant and unanticipated headwinds" that impacted the quarter's performance. However, he maintained an optimistic stance on the fundamental demand for the company's services and the long-term growth prospects of the ambulatory surgical center (ASC) market. In an effort to boost investor confidence, Surgery Partners announced a new share repurchase program on February 26, authorizing buybacks of up to $200 million. Nevertheless, the company's fiscal 2026 sales guidance, projected between $3.35 billion and $3.45 billion, fell short of the $3.56 billion consensus, further fueling market apprehension. Technical indicators signal a bearish trend, with the stock trading well below its 20-day and 100-day simple moving averages. The Relative Strength Index (RSI) is neutral at 44.45, while the Moving Average Convergence Divergence (MACD) shows a bearish crossover at 0.15, below its signal line of 0.22. This confluence of factors sent SGRY shares down 23.93% to $12.08 in premarket trading, marking a new 52-week low.
This situation highlights the precarious balance companies must maintain between growth ambitions and realistic financial projections. Even with strategic initiatives like share buybacks and a focus on higher-acuity procedures, external pressures and unmet expectations can significantly sway market sentiment. For investors, this serves as a reminder to scrutinize not just top-line growth but also profitability, cash flow, and management's guidance, as these often provide a more complete picture of a company's health and future trajectory.